NEW YORK (GenomeWeb News) – The University of Manchester's Institute of Cancer Sciences said today that it will lead an international consortium that will use €6 million ($7.9 million) in funding to develop genetic biomarkers to identify patients who are at risk of developing long-term side effects from radiation therapy.

The 13 members involved in the EU-funded project, called REQUITE, plan to develop these markers specifically for patients with breast, prostate, and lung cancer who receive radiation therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.